Application of single nucleotide polymorphism of ABCB1 gene in predicting the prognosis of patients with primary central nervous system lymphoma
By detecting single nucleotide polymorphism sites rs1045642 and rs2032582 of the ABCB1 gene, a prognosis prediction system was constructed, which solved the problem that the current technology could not effectively predict the response of PCNSL patients to methotrexate, and achieved the prognosis of PCNSL patients Effective evaluation and guidance of chemotherapy regimens have improved the therapeutic effect.
Patent Information
- Application Number
- CN202310045986.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-01-30
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2043-01-30
AI Technical Summary
Existing treatment options are unable to effectively predict differences in response to methotrexate treatment in patients with primary central nervous system lymphoma (PCNSL), resulting in uncertain prognosis.
The single nucleotide polymorphic sites of the ABCB1 gene were detected, and the prognosis prediction system was constructed to predict the patient's prognosis through genotype scores, and chemotherapy regimen was guided.
By detecting single nucleotide polymorphic sites of the ABCB1 gene, the prognosis of PCNSL patients can be effectively predicted, divided into low-risk, medium-risk and high-risk groups, guiding chemotherapy plans and improving treatment effects.
Smart Images

Figure CN116004832B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and in particular to application of single nucleotide polymorphism of ABCB1 gene in predicting the prognosis of patients with primary central nervous system lymphoma (PCNSL). Background Art
[0002] PCNSL is a rare extranodal invasive non-Hodgkin's lymphoma with an incidence of 0.47 / 100,000 people / year, accounting for about 1% of the incidence of lymphoma and 3% of primary central nervous system tumors. The disease often occurs in the brain, spinal cord, leptomeninges and eyes, rarely involving the whole body, and more than 90% of the tissue types are diffuse large B-cell lymphoma. The 5-year survival rate of PCNSL is only 30%. To date, high-dose methotrexate (MTX)-based regimens have become the first-line treatment for PCNSL because they can greatly improve the prognosis of PCNSL. However, different patients have different prognoses using the same treatment regimen. Studies have shown that single nucleotide polymorphisms, as one of the main forms of genetic variation in the body, can lead to individual differences in pharmacodynamics. Screening patients for single nucleotide polymorphisms before medication is of great significance for predicting the prognosis of patients.
[0003] MTX is an antimetabolite antitumor drug that exerts its cytotoxic effect mainly by competitively inhibiting dihydrofolate reductase (DHFR). In vivo, MTX enters cells through reduced folate carriers (the solute carrier family 19 member 1, SLC19A1 or the solute carrier organic anion transporter 1B1 family, SLCO1B1) on the cell surface. In the cytoplasm, MTX can be polyglutamylated by folate polyglutamate synthase (FPGS), thereby enhancing its intracellular retention. Gamma-glutamyl hydrolase (GGH) can reverse this process and promote the excretion of MTX from the cytoplasm. MTX and MTX polyglutamate polymers (MTX-PGs) deplete tetrahydrofolate by inhibiting DHFR, thereby affecting nucleic acid synthesis. MTX-PGs can also inhibit thymidylate synthase (TYMS) and 5-aminoimidazole-4-carboxamide ribonucleotide transformylase (ATIC), leading to the blockage of purine and pyrimidine nucleotide synthesis. S It can act on methylenetetrahydrofolate reductase (MTHFR), methionine transferase reductase (MTRR) and methionine synthase (MTR) to produce cytotoxic effects. Finally, MTX is transported and eliminated against the concentration gradient by cell efflux transporters such as ABCC2 and ABCB1 through ATP hydrolysis. The activity of key enzymes in the MTX action pathway and the expression of coding genes may affect the efficacy of MTX. Therefore, detecting single nucleotide polymorphisms of related genes in the MTX action pathway may predict the prognosis of PCNSL. Summary of the invention
[0004] In order to overcome the defects in the prior art, the present invention provides the application of ABCB1 rs1045642 and rs2032582 single nucleotide polymorphisms in predicting the prognosis of PCNSL patients.
[0005] To achieve the above object, the present invention adopts the following technical solution:
[0006] The invention provides the use of a reagent for detecting a single nucleotide polymorphism site of an ABCB1 gene in preparing a product for predicting the prognosis of a patient with primary central nervous system lymphoma. The single nucleotide polymorphism site is rs1045642 and / or rs2032582.
[0007] Furthermore, the above-mentioned primary central nervous system lymphoma patients are patients receiving methotrexate alone or in combination with chemotherapy.
[0008] Furthermore, the prediction criteria of the above product are: for the rs1045642 locus, when the genotype is GG, the patient's prognosis is poor; when carrying the A allele, the prognosis is good; and / or
[0009] For the rs2032582 locus, when the patient carries the G allele, the prognosis is poor, and when the patient does not carry the G allele, the prognosis is good.
[0010] Furthermore, the above product includes a prognosis prediction system; the prognosis prediction system is: for the rs1045642 site, when the patient carries the A allele, it is scored as 1 point, and when the patient does not carry the A allele, it is scored as 0 point; for the rs2032582 site, when the patient carries the G allele, it is scored as 0 point, and when the patient does not carry the G allele, it is scored as 1 point; the sum of the two scores is the patient's total score; when the patient scores 2 points, the average PFS is 28.8 months, when the patient scores 1 point, the average PFS is 21.6 months, and when the patient scores 0 points, the average PFS is 15.2 months.
[0011] Further, the above reagents include reagents for detecting the genotype of the above single nucleotide polymorphism sites by matrix-assisted laser desorption ionization time-of-flight mass spectrometry, pyrophosphate sequencing, enzyme-amplified polymorphic sequence method, direct sequencing, single base extension, allele-specific probe hybridization, allele-specific primer extension, allele-specific amplification, allele-specific nucleotide incorporation, 5' nuclease digestion, molecular beacon assay, oligonucleotide ligation assay, size analysis and single-stranded conformation polymorphism method.
[0012] Furthermore, the above reagent is a nucleic acid affinity ligand for the above single nucleotide polymorphism site.
[0013] Furthermore, the above-mentioned nucleic acid affinity ligand is a primer or a probe.
[0014] Furthermore, the above reagents include primers whose sequences are selected from SEQ ID NOs. 1 to 6.
[0015] The present invention adopts the above technical solution, and has the following technical effects compared with the prior art:
[0016] The present invention first discovered that the genotypes of the single nucleotide polymorphism sites ABCB1 rs1045642 and rs2032582 of the ABCB1 gene can be used to predict the prognosis of patients with primary central nervous system lymphoma, and constructed a prognosis prediction system that can be used to guide clinical drug use. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 Survival curve and log-Rank test were used to analyze the effect of single nucleotide polymorphism of ABCB1 rs1045642 on the prognosis of PCNSL patients;
[0018] Figure 2 Survival curves and log-Rank test were used to analyze the effect of single nucleotide polymorphism of ABCB1 rs2032582 on the prognosis of PCNSL patients;
[0019] Figure 3 Survival curves and log-Rank tests were used to analyze the impact of the prediction system composed of single nucleotide polymorphisms of ABCB1rs1045642 and rs2032582 on the prognosis of PCNSL patients. DETAILED DESCRIPTION
[0020] The present invention provides the application of ABCB1 rs1045642 and rs2032582 single nucleotide polymorphisms in predicting the prognosis of PCNSL patients. The present invention is described in detail and specifically through specific examples and drawings below to better understand the present invention, but the following examples do not limit the scope of the present invention.
[0021] The methods in the examples are conventional methods unless otherwise specified, and the reagents used are conventional commercial reagents or reagents prepared according to conventional methods unless otherwise specified.
[0022] Example 1
[0023] 1. Samples: Peripheral blood from patients with primary central nervous system lymphoma.
[0024] 113 PCNSL patients treated with methotrexate alone or in combination with chemotherapy, with an average age of 57.6±11.7 years and a male-female ratio of 74:39. Patients underwent cranial MRI evaluation before each chemotherapy, and disease progression was evaluated every 3-6 months after chemotherapy or when clinically required. Specific patient clinical information is shown in Table 1 below.
[0025] Table 1 Basic data of 113 PCNSL patients treated with methotrexate chemotherapy
[0026]
[0027] a, The continuous variables that conformed to normal distribution were expressed as mean ± standard deviation
[0028] b ,The results of continuous variables that do not conform to normal distribution are expressed as median (range)
[0029] According to the consensus guidelines of the International Primary Central Nervous System Lymphoma Collaborative Group (IPCG), the treatment response is evaluated after 3-4 courses of chemotherapy, including complete remission (CR), partial remission (PR), progressive disease (PD) and stable disease (SD). PD refers to: an increase of more than 25% in contrast-enhanced lesions shown on MRI; an increase in vitreous cell counts; progressive retinal or optic nerve infiltration; the appearance of new lesions at the original lesion site, or the lesions involving new sites. Progression-free survival (PFS) refers to the time from the start of treatment to the first occurrence of PD.
[0030] Take 300 μl of sample blood, extract DNA according to the instructions of the kit, and detect the DNA concentration and purity using an ultraviolet spectrophotometer.
[0031] 2. ABCB1 rs1045642A / G and rs2032582G / T / A allele genotype detection
[0032] The present invention detected the genotypes of a total of 42 sites on 12 genes including SLCO1B1, SLC19A1, ABCC2, ABCB1, FPGS, GGH, DHFR, TYMS, ATIC, MTHFR, MTRR, and MTR on the MTX action pathway. The distribution of the 42 single nucleotide polymorphism sites on chromosomes and the allele frequency information are shown in Table 2 below. Since the rs161871 site does not meet the HW balance in the PCNSL patients studied, the site is not analyzed when statistics are performed.
[0033] Table 2 Distribution of genes related to MTX action pathway
[0034]
[0035]
[0036] : The minimum allele frequency of this allele in this study
[0037] :The minimum allele frequency of this allele in Chinese Han population in the HAPMAP database
[0038] The genotyping method is matrix-assisted laser desorption ionization time-of-flight mass spectrometry. The principle is to first amplify the target sequence by PCR, then add a sequence-specific extension primer of the single nucleotide polymorphism site, thereby extending one base at the corresponding site. The prepared sample analyte is co-crystallized with the chip matrix, the crystal is placed in the vacuum tube of the mass spectrometer, and then the instantaneous nanosecond (10 -9 s) Strong laser excitation, due to the energy absorbed by the matrix molecules through radiation, leads to energy accumulation and rapid heat generation, thus sublimating the matrix crystals, and the nucleic acid molecules will desorb and transform into metastable ions. The ions produced are mostly single-charged ions. These single-charged ions obtain the same kinetic energy in the accelerating electric field, and then are separated according to their mass-to-charge ratio in a non-electric field drift region, and fly in a vacuum tube to reach the detector. The results were analyzed using MassARRAY Typer 4.0 software.
[0039] The specific experimental steps are as follows:
[0040] (1) 300 μl of blood was collected from the 113 PCNSL patients treated with methotrexate alone or in combination with chemotherapy, and DNA was extracted according to the kit instructions;
[0041] (2) PCR reaction to amplify the target gene fragment:
[0042] 1) 5 μL system, containing 1 μL DNA template, 1 μL primer mixture (10 pmol / μL) (wherein, the primer sequences of ABCB1 rs1045642 and rs2032582 are shown in Tables 3 and 4 below), 0.625 μL PCR buffer (10×), 0.325 μL MgCl2 (25 mM), 1 μL dNTP (2.5 mM), 0.1 μL HostarTaq (5 U / μL), and 0.95 μL sterile water;
[0043] 2) PCR conditions: 95°C for 15 min → (94°C for 20 sec → 56°C for 30 sec → 72°C for 1 min) × 40 cycles → 72°C for 3 min.
[0044] (3) Treatment with SAP (Shrimp alkaline phosphatase) to remove free dNTPs in the system: Add 2 μL of SAP reaction solution to each well of the PCR reaction solution in process (2) and place in a PCR instrument: 37°C 40 min → 85°C 5 min → 4°C ∞.
[0045] (4) Single base extension reaction: Add 2 μl of iPlex reaction solution to each well of the PCR reaction solution in process (3), place in a PCR instrument, and perform the following reaction:
[0046] 95℃30sec→(94℃5sec→(52℃5sec→80℃5sec)×5cycles)×40cycles→72℃3min→4℃∞
[0047] (5) Product purification;
[0048] (6) Nanodispenser SpectroCHIP chip spotting;
[0049] (7) MassARRAY Analyzer Compac mass spectrometry;
[0050] (8) MassARRAY Typer 4.0 software was used to analyze the experimental results and obtain typing data.
[0051] Table 3 PCR primers and site extension primers used for ABCB1 rs1045642 genotyping
[0052] type sequence SEQ ID NO. PCR Primer (Forward) ACGTTGGAATAAGGCATGTATGTTGGCCTC SEQ ID NO.1 PCR Primer (Reverse) ACGTTGGATGGCTGAGAACATTGCCTATGG SEQ ID NO.2 Single base extension primer aCCTCCTTTGCTGCCCTCAC SEQ ID NO.3
[0053] Table 4 PCR primers and site extension primers used for ABCB1 rs2032582 genotyping
[0054] type sequence SEQ ID NO. PCR Primer (Forward) ACGTTGGATGCATATTTAGTTTGACTCACC SEQ ID NO.4 PCR Primer (Reverse) ACGTTGGATGGAAAATGTTGTCTGGACAAGC SEQ ID NO.5 Single base extension primer atatgTAGTTTGACTCACCTTCCCAG SEQ ID NO.6
[0055] 3. Statistical analysis:
[0056] SPSS 20.0 software was used for statistical analysis. Continuous variables were expressed as mean and standard deviation or quartile. Categorical variables were expressed as proportions. The Kolmogorov-Smirnov test was used for the normal distribution of continuous variables. The independent sample t test was used for the mean test of normally distributed continuous variables. The Mann-Whitney U test was used for the mean of non-normally distributed continuous variables. The effect of SNP on PFS in PCNSL patients was analyzed by KM analysis and log-rank test. The effects of GCB subtype, PS score, chemotherapy regimen, LDH level, β2 microglobulin, whether deep involvement, number of lesions, whether surgical resection was performed, and the content of protein, glucose and chloride in cerebrospinal fluid on PFS were analyzed by univariate Cox analysis. In log-rank and univariate Cox analysis, all variables with P < 0.1 were included in the multivariate Cox regression analysis together with age, gender, height, and EGOG score. The statistical significance level was set at P less than 0.05.
[0057] IV. Results
[0058] Table 5 shows the results of univariate analysis of the effects of SNP on 113 PCNSL patients. Five loci, including DHFRrs1650697, TYMSrs2847153, MTRRrs7730643, ABCB1rs1045642 and ABCB1rs2032582, were included in the subsequent multivariate Cox regression analysis because P<0.1. Similarly, in the univariate Cox analysis of the effects of clinical factors on PFS, LDH and protein levels in cerebrospinal fluid were also included in the multivariate Cox regression analysis because P<0.1.
[0059] Table 5 Log-rank test of the effect of SNP on PFS in PCNSL patients
[0060]
[0061]
[0062] As shown in Table 6, in the multivariate Cox regression analysis including age, sex, height, ECOG score, LDH level, cerebrospinal fluid protein level and corresponding genotype, ABCB1 rs1045642 and rs2032582 were both associated with PFS. The probability of disease progression in patients with ABCB1rs1045642GG genotype was 1.972 times that of A allele carriers (95%CI: 1.090-3.566; P=0.025). The probability of disease progression in patients with ABCB1rs2032582G allele was 2.250 times that of patients without G allele (95%CI: 1.058-4.785; P=0.035).
[0063] Figure 1 The KM curve shown is the effect of ABCB1 rs1045642 on PFS of 113 PCNSL patients. It can be seen from the figure that the progression-free survival rate of patients with ABCB1rs1045642GG genotype is lower than that of A allele carriers at the same time (P=0.012).
[0064] Figure 2 The KM curve shown is the effect of ABCB1 rs2032582 on PFS of 113 PCNSL patients. It can be seen from the figure that the progression-free survival rate of patients carrying ABCB1 rs2032582G allele is lower than that of non-carriers of G allele at the same time (P=0.004).
[0065] Table 6 Multivariate Cox regression analysis of the impact of factors on PFS
[0066]
[0067] In summary, we found that both ABCB1 rs1045642 and rs2032582 had an impact on the patient's PFS, suggesting that these two sites can be used as biomarkers for the prognosis of PCNSL patients after MTX chemotherapy. Next, we further explored the correlation between the prediction system composed of the two SNP sites of ABCB1rs1045642 and rs2032582 and the progression-free survival of PCNSL patients receiving methotrexate monotherapy or combined chemotherapy.
[0068] We constructed a predictive scoring system based on two SNP loci, ABCB1 rs1045642A / G and rs2032582G / T / A alleles. Specifically, for the rs1045642 locus, when the patient carries the A allele, it is scored as 1 point, and when the patient does not carry the A allele, it is scored as 0 point. For the rs2032582 locus, when the patient carries the G allele, it is scored as 0 point, and when the patient does not carry the G allele, it is scored as 1 point. The total score was calculated for each patient. According to the above scoring system, patients can be divided into 3 groups (0 points, 1 point, 2 points), and then KM analysis and log-rank test were performed on 113 PCNSL patients. The results showed that when the patient scored 2 points, the average PFS was 28.8 months (95% confidence interval: 22.8-34.9 months), which can be considered as a low-risk group for disease progression; when the patient scored 1 point, the average PFS was 21.6 months (95% confidence interval: 15.5-27.6 months), which can be considered as a medium-risk group for disease progression; when the patient scored 0 points, the average PFS was 15.2 months (95% confidence interval: 8.0-22.4 months), which can be considered as a high-risk group. There was a significant difference in PFS between patients in different scoring groups (P = 0.003, such as Figure 3 ).
[0069] The specific embodiments of the present invention are described in detail above, but they are only examples, and the present invention is not limited to the specific embodiments described above. For those skilled in the art, any equivalent modification and substitution of the present invention are also within the scope of the present invention. Therefore, the equalization and modification made without departing from the spirit and scope of the present invention should be included in the scope of the present invention.
Claims
1. Detection ABCB1 Application of a reagent for single nucleotide polymorphism sites of a gene in the preparation of a product for predicting the prognosis of patients with primary central nervous system lymphoma, It is characterized in that The single nucleotide polymorphism sites are rs1045642 and rs2032582; the primary central nervous system lymphoma patients are patients receiving methotrexate monotherapy or combined chemotherapy.
2. The use according to claim 1, It is characterized in that The prediction criteria of the product are: for the rs1045642 locus, when the genotype is GG, the patient's prognosis is poor; when carrying the A allele, the prognosis is good; and, For the rs2032582 locus, when the patient carries the G allele, the prognosis is poor, and when the patient does not carry the G allele, the prognosis is good.
3. The use according to claim 1, It is characterized in that The product includes a prognosis prediction system; the prognosis prediction system is: for the rs1045642 site, when the patient carries the A allele, it is scored as 1 point, and when the patient does not carry the A allele, it is scored as 0 point; for the rs2032582 site, when the patient carries the G allele, it is scored as 0 point, and when the patient does not carry the G allele, it is scored as 1 point; the sum of the two scores is the patient's total score; when the patient scores 2 points, the average PFS is 28.8 months, when the patient scores 1 point, the average PFS is 21.6 months, and when the patient scores 0 points, the average PFS is 15.2 months.
4. The use according to claim 1, It is characterized in that The reagent is a nucleic acid affinity ligand for the single nucleotide polymorphism site.
5. The use according to claim 4, It is characterized in that The nucleic acid affinity ligand is a primer or a probe.
6. The use according to claim 1, It is characterized in that The reagents include primers whose sequences are selected from SEQ ID NO.1-6.
Citation Information
Patent Citations
Fluorescence probe group and detection reagent for predicting curative effects and adverse reactions of methotrexate
CN106957912A
SNP combination and application of SNP combination in preparation of product for detecting drug reaction related genes
CN108998515A
Primer group and method for detecting chemotherapy drug curative effect and side effect related SNP
CN110257523A
Establishment method and application of primary central nervous system lymphoma prognosis model based on albumin and ECOG-PS
CN113470753A
